Oblita Therapeutics
Oostmallebaan 87
2980 Zoersel
BE
Oblita Therapeutics
Foundation date
08/03/2016
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.
Upcoming events
All events-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté
Latest news
More newsJobs
More jobs-
-
-
30/10/24
Flemish Brabant
Professor in Food Microbiology: Applications of microbes in the food chain (ref. ZAP-2024-87)
Permanent
KU Leuven
More info?
Ellen Telleir
Communication Coordinator